Sugar-coating wound repair: A review of FGF-10 and dermatan sulfate in wound healing and their potential application in burn wounds

Journal of Burn Care and Research

Volumn 33, Issue 3, 2012, Pages 299-310

  Plichta, Jennifer K ^a   Radek, Katherine A ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CHONDROITIN SULFATE; DERMATAN SULFATE; FIBROBLAST GROWTH FACTOR 10; FIBROBLAST GROWTH FACTOR RECEPTOR; GAG PROTEIN; GLYCOSAMINOGLYCAN; HEPARAN SULFATE; HEPARIN; HEPARIN COFACTOR II; HYALURONIC ACID; KERATAN SULFATE; KERATINOCYTE GROWTH FACTOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; POLYPEPTIDE ANTIBIOTIC AGENT; PROTEOGLYCAN; SUGAR;

BINDING SITE; BLOOD CLOTTING DISORDER; BURN; CARCINOGENESIS; CELL ACTIVITY; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; COLITIS; COMORBIDITY; DIABETES MELLITUS; DISEASE MODEL; ENZYME ACTIVITY; EPITHELIZATION; HOMEOSTASIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KERATINOCYTE; KIDNEY FAILURE; MICROENVIRONMENT; MORTALITY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; TISSUE REPAIR; URETER OBSTRUCTION; WOUND FLUID; WOUND HEALING;

BURNS; CELL PROLIFERATION; DERMATAN SULFATE; DRUG THERAPY, COMBINATION; FEMALE; FIBROBLAST GROWTH FACTOR 10; HUMANS; INJURY SEVERITY SCORE; KERATINOCYTES; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGENERATION; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; WOUND HEALING;

EID: 84861173058     PISSN: 1559047X     EISSN: 15590488     Source Type: Journal    
DOI: 10.1097/BCR.0b013e318240540a     Document Type: Review

References (100)

1. American Burn Association. Burn incidence and treatment in the United States: 2011 Fact Sheet. 2011; available from: http://www.ameriburn.org/ resources-factsheet.php; Internet; accessed August 26, 2011.
2. American Burn Association. 2011 National Burn Repository: Report of Data from 2001-2010. Chicago, IL: American Burn Association; 2011.
3. Atiyeh BS, Gunn SW, Hayek SN. State of the art in burn treatment. World J Surg 2005;29:131-48. (Pubitemid 40576458)
4. Powers CJ, McLeskey SW, Wellstein A. Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer 2000;7:165-97.
5. Ornitz DM, Itoh N. Fibroblast growth factors. Genome Biol 2001;2:3005.1-3005.12.
6. Ornitz DM. FGFs, heparan sulfate and FGFRs: complex interactions essential for development. Bioessays 2000;22:108-12. (Pubitemid 30092077)
7. Eswarakumar VP, Lax I, Schlessinger J. Cellular signaling by fbroblast growth factor receptors. Cytokine Growth Factor Rev 2005;16:139-49. (Pubitemid 40616112)
8. Igarashi M, Finch PW, Aaronson SA. Characterization of recombinant human fbroblast growth factor (FGF)-10 reveals functional similarities with keratinocyte growth factor (FGF-7). J Biol Chem 1998;273:13230-5. (Pubitemid 28246895)
9. Radek KA, Taylor KR, Gallo RL. FGF-10 and specifc structural elements of dermatan sulfate size and sulfation promote maximal keratinocyte migration and cellular proliferation. Wound Repair Regen 2009;17:118-26.
10. Werner S, Smola H, Krieg T, et al. The function of KGF in morphogenesis of epithelium and reepithelialization of wounds. Science 1994;266:819-22. (Pubitemid 24359294)
11. Yang J, Meyer M, Muller AK, et al. Fibroblast growth factor receptors 1 and 2 in keratinocytes control the epidermal barrier and cutaneous homeostasis. J Cell Biol 2010;188:935-52.
12. Zhang X, Ibrahimi OA, Olsen SK, Umemori H, Moham-madi M, Ornitz DM. Receptor specifcity of the fbroblast growth factor family. The complete mammalian FGF family. J Biol Chem 2006;281:15694-700. (Pubitemid 43848456)
13. Komi-Kuramochi A, Kawano M, Oda Y, et al. Expression of fbroblast growth factors and their receptors during full-thickness skin wound healing in young and aged mice. J Endocrinol 2005;186:273-89. (Pubitemid 41167397)
14. Beer HD, Bittner M, Niklaus G, et al. The fbroblast growth factor binding protein is a novel interaction partner of FGF-7, FGF-10 and FGF-22 and regulates FGF activity: implications for epithelial repair. Oncogene 2005;24:5269-77.
15. Nakatake Y, Hoshikawa M, Asaki T, Kassai Y, Itoh N. Iden-tifcation of a novel fbroblast growth factor, FGF-22, preferentially expressed in the inner root sheath of the hair follicle. Biochim Biophys Acta 2001;1517:460-3. (Pubitemid 32126602)
16. Beer HD, Florence C, Dammeier J, McGuire L, Werner S, Duan DR. Mouse fbroblast growth factor 10: cDNA cloning, protein characterization, and regulation of mRNA expression. Oncogene 1997;15:2211-8. (Pubitemid 27493910)
17. Ceccarelli S, Cardinali G, Aspite N, et al. Cortactin involvement in the keratinocyte growth factor and fbroblast growth factor 10 promotion of migration and cortical actin assembly in human keratinocytes. Exp Cell Res 2007;313:1758-77. (Pubitemid 46653878)
18. Danilenko DM, Ring BD, Tarpley JE, et al. Growth factors in porcine full and partial thickness burn repair. Differing targets and effects of keratinocyte growth factor, platelet-derived growth factor-BB, epidermal growth factor, and neu differentiation factor. Am J Pathol 1995;147:1261-77.
19. Albornoz C, Villegas J, Sylvester M, Pena V, Bravo I. Burns are more aggressive in the elderly: proportion of deep burn area/total burn area might have a role in mortality. Burns 2011;37:1058-61.
20. O'Toole EA. Extracellular matrix and keratinocyte migration. Clin Exp Dermatol 2001;26:525-30. (Pubitemid 32955467)
21. Pastar I, Stojadinovic O, Tomic-Canic M. Role of kera-tinocytes in healing of chronic wounds. Surg Technol Int 2008;17:105-12.
22. Werner S, Krieg T, Smola H. Keratinocyte-fbroblast interactions in wound healing. J Invest Dermatol 2007;127:998-1008.
23. Emoto H, Tagashira S, Mattei MG, et al. Structure and expression of human fbroblast growth factor-10. J Biol Chem 1997;272:191-4.
24. Derrick T, Grillo AO, Vitharana SN, et al. Effect of polyan-ions on the structure and stability of repifermin (keratino-cyte growth factor-2). J Pharm Sci 2007;96:761-76. (Pubitemid 46657867)
25. Kamerzell TJ, Unruh JR, Johnson CK, Middaugh CR. Conformational fexibility, hydration and state parameter fuctuations of fbroblast growth factor-10: effects of ligand binding. Biochemistry 2006;45:15288-300. (Pubitemid 46049576)
26. Ohuchi H, Hori Y, Yamasaki M, et al. FGF10 acts as a major ligand for FGF receptor 2 IIIB in mouse multi-organ development. Biochem Biophys Res Commun 2000;277:643-9.
27. Sekine K, Ohuchi H, Fujiwara M, et al. FGF10 is essential for limb and lung formation. Nat Genet 1999;21:138-41. (Pubitemid 29036301)
28. Ohuchi H, Tao H, Ohata K, et al. Fibroblast growth factor 10 is required for proper development of the mouse whiskers. Biochem Biophys Res Commun 2003;302:562-7. (Pubitemid 36279567)
29. Suzuki K, Yamanishi K, Mori O, et al. Defective terminal differentiation and hypoplasia of the epidermis in mice lacking the FGF10 gene. FEBS Lett 2000;481:53-6. (Pubitemid 30662376)
30. Jang JH. Stimulation of human hair growth by the recombi-nant human keratinocyte growth factor-2 (KGF-2). Biotech-nol Lett 2005;27:749-52.
31. Marchese C, Felici A, Visco V, et al. Fibroblast growth factor 10 induces proliferation and differentiation of human primary cultured keratinocytes. J Invest Dermatol 2001;116:623-8. (Pubitemid 32299856)
32. Yang Y, Fu X, Li J. Effect of keratinocyte growth factor-2 on proliferation of human adult keratinocytes. Chin J Trauma-tol 2002;5:342-5. (Pubitemid 43020527)
33. Satoh A, Makanae A, Wada N. The apical ectodermal ridge (AER) can be re-induced by wounding, wnt-2b, and fgf-10 in the chicken limb bud. Dev Biol 2010;342:157-68.
34. Wang X, Zhou X, Ma J, et al. Effects of keratinocyte growth factor-2 on corneal epithelial wound healing in a rabbit model of carbon dioxide laser injury. Biol Pharm Bull 2010;33:971-6.
35. Liu L, Li Y, Huang S, Lin J, Zhang W. Keratinocyte growth factor-2 on the proliferation of corneal epithelial stem cells in rabbit alkali burned cornea. Yan Ke Xue Bao 2007;23:107-16.
36. Tagashira S, Harada H, Katsumata T, Itoh N, Nakatsuka M. Cloning of mouse FGF10 and up-regulation of its gene expression during wound healing. Gene 1997;197:399-404. (Pubitemid 27399918)
37. Jimenez PA, Rampy MA. Keratinocyte growth factor-2 accelerates wound healing in incisional wounds. J Surg Res 1999;81:238-42. (Pubitemid 29397817)
38. Xia YP, Zhao Y, Marcus J, et al. Effects of keratinocyte growth factor-2 (KGF-2) on wound healing in an ischaemia-impaired rabbit ear model and on scar formation. J Pathol 1999;188:431-8. (Pubitemid 29327443)
39. Soler PM, Wright TE, Smith PD, et al. In vivo characterization of keratinocyte growth factor-2 as a potential wound healing agent. Wound Repair Regen 1999;7:172-8.
40. Robson MC, Phillips TJ, Falanga V, et al. Randomized trial of topically applied repifermin (recombinant human kerati-nocyte growth factor-2) to accelerate wound healing in venous ulcers. Wound Repair Regen 2001;9:347-52. (Pubitemid 34038762)
41. Stump DC, Parrott J. Human genome sciences reports results of clinical trial of repifermin in patients with chronic venous ulcers. Rockville, MD: Human Genome Sciences; 2003.
42. Stump DC, Parrott J. Human genoma sciences reports results of phase 2 clinical trial of repifermin in patients with cancer therapy-induced mucositis. Rockville, MD: Human Genome Sciences; 2004.
43. Han DS, Li F, Holt L, et al. Keratinocyte growth factor-2 (FGF-10) promotes healing of experimental small intestinal ulceration in rats. Am J Physiol Gastrointest Liver Physiol 2000;279:G1011-22.
44. Miceli R, Hubert M, Santiago G, et al. Effcacy of keratinocyte growth factor-2 in dextran sulfate sodium-induced murine colitis. J Pharmacol Exp Ther 1999; 209:464-71. (Pubitemid 29302357)
45. Sandborn WJ, Sands BE, Wolf DC, et al. Repifermin (ke-ratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Aliment Pharmacol Ther 2003;17:1355-64. (Pubitemid 36774142)
46. Smith PD, Polo M, Soler PM, et al. Effcacy of growth factors in the accelerated closure of interstices in explanted meshed human skin grafts. J Burn Care Rehabil 2000;21 (1 Pt 1):5-9. (Pubitemid 30062875)
47. Raman R, Sasisekharan V, Sasisekharan R. Structural insights into biological roles of protein-glycosaminoglycan interactions. Chem Biol 2005;12:267-77. (Pubitemid 40406273)
48. Guimond S, Maccarana M, Olwin BB, Lindahl U, Rapraeger AC. Activating and inhibitory heparin sequences for FGF-2 (basic FGF). Distinct requirements for FGF-1, FGF-2, and FGF-4. J Biol Chem 1993;268:23906-14. (Pubitemid 23335365)
49. Kan M, Wang F, Xu J, Crabb JW, Hou J, McKeehan WL. An essential heparin-binding domain in the fbroblast growth factor receptor kinase. Science 1993;259:1918-21. (Pubitemid 23124467)
50. Saksela O, Moscatelli D, Sommer A, Rifkin DB. Endothe-lial cell-derived heparan sulfate binds basic fbroblast growth factor and protects it from proteolytic degradation. J Cell Biol 1988;107:743-51.
51. Vlodavsky I, Bar-Shavit R, Ishai-Michaeli R, Bashkin P, Fuks Z. Extracellular sequestration and release of fbroblast growth factor: a regulatory mechanism? Trends Biochem Sci 1991;16:268-71.
52. Gandhi NS, Mancera RL. The structure of glycosaminogly-cans and their interactions with proteins. Chem Biol Drug Des 2008;72:455-82.
53. Taylor KR, Gallo RL. Glycosaminoglycans and their proteo-glycans: host-associated molecular patterns for initiation and modulation of infammation. FASEB J 2006;20:9-22. (Pubitemid 43100470)
54. Yamada S, Sugahara K. Potential therapeutic application of chondroitin sulfate/dermatan sulfate. Curr Drug Discov Technol 2008;5:289-301.
55. Trowbridge JM, Gallo RL. Dermatan sulfate: new functions from an old glycosaminoglycan. Glycobiology 2002;12:117R-25R.
56. Gospodarowicz D, Cheng J. Heparin protects basic and acidic FGF from inactivation. J Cell Physiol 1986;128:475-84. (Pubitemid 16015532)
57. Casu B, Guerrini M, Torri G. Structural and conforma-tional aspects of the anticoagulant and anti-thrombotic activity of heparin and dermatan sulfate. Curr Pharma Des 2004;77:123-35.
58. Taylor KR, Rudisill JA, Gallo RL. Structural and sequence motifs in dermatan sulfate for promoting fbroblast growth factor-2 (FGF-2) and FGF-7 activity. J Biol Chem 2005;280:5300-6. (Pubitemid 40280003)
59. Trowbridge JM, Rudisill JA, Ron D, Gallo RL. Dermatan sulfate binds and potentiates activity of keratinocyte growth factor (FGF-7). J Biol Chem 2002;277:42815-20. (Pubitemid 35285657)
60. Brown CT, Applebaum E, Banwatt R, Trinkaus-Randall V. Synthesis of stromal glycosaminoglycans in response to injury. J Cell Biochem 1995;59:57-68.
61. Kim CW, Goldberger OA, Gallo RL, Bernfeld M. Members of the syndecan family of heparan sulfate proteoglycans are expressed in distinct cell-, tissue-, and development-specifc patterns. Mol Biol Cell 1994;5:797-805. (Pubitemid 24254349)
62. Oksala O, Salo T, Tammi R, et al. Expression of proteogly-cans and hyaluronan during wound healing. J Histochem Cytochem 1995;43:125-35.
63. Tumova S, Woods A, Couchman JR. Heparan sulfate pro-teoglycans on the cell surface: versatile coordinators of cellular functions. Int J Biochem Cell Biol 2000;32:269-88. (Pubitemid 30069970)
64. Cosmi B, Fredenburgh JC, Rischke J, Hirsh J, Young E, Weitz JI. Effect of nonspecifc binding to plasma proteins on the antithrombin activities of unfractionated heparin, low-molecular-weight heparin, and dermatan sulfate. Circulation 1997;95:118-24. (Pubitemid 27029952)
65. Malavaki C, Mizumoto S, Karamanos N, Sugahara K. Recent advances in the structural study of functional chondroitin sulfate and dermatan sulfate in health and disease. Connect Tissue Res 2008;49:133-9.
66. Penc SF, Pomahac B, Winkler T, et al. Dermatan sulfate released after injury is a potent promoter of fbroblast growth factor-2 function. J Biol Chem 1998;273:28116-21. (Pubitemid 28496107)
67. Lee PHA, Trowbridge JM, Taylor KR, Morhenn VB, Gallo RL. Dermatan sulfate proteoglycan and glycosamin-oglycan synthesis is induced in fbroblasts by transfer to a three-dimensional extracellular environment. J Biol Chem 2004;279:48640-6. (Pubitemid 39625739)
68. Danielson KG, Baribault H, Holmes DF, Graham H, Ka-dler KE, Iozzo RV. Targeted disruption of decorin leads to abnormal collagen fbril morphology and skin fragility. J Cell Biol 1997;136:729-43. (Pubitemid 27083772)
69. Scott P, Dodd C, Ghahary A, Shen Y, Tredget E. Fibro-blasts from post-burn hypertrophic scar tissue synthesize less decorin than normal dermal fbroblasts. Clin Sci (Lond) 1998;94:541-7. (Pubitemid 28205921)
70. Kozlowski E, Pavao M, Borsig L. Ascidian dermatan sulfates attenuate metastasis, infammation and thrombosis by inhibition of P-selectin. J Thromb Haemost 2011;9:1807-15.
71. Penc SF, Pomahac B, Eriksson E, Detmar M, Gallo RL. Der-matan sulfate activates nuclear factor-kappab and induces en-dothelial and circulating intercellular adhesion molecule-1. J Clin Invest 1999;103:1329-35. (Pubitemid 29218303)
72. Wang J, Lee J, Yan M, Rho J, Roehrl M. Dermatan sulfate interacts with dead cells and regulates CD5(+) B-cell fate: implications for a key role in autoimmunity. Am J Pathol 2011;178:2168-76.
73. Rho J, Zhang W, Murali M, Roehrl M, Wang J. Human proteins with affnity for dermatan sulfate have the propensity to become autoantigens. Am J Pathol 2011;178:2177-90.
74. Belmiro C, Castelo-Branco M, Melim L, et al. Unfraction-ated heparin and new heparin analogues from ascidians (chordate-tunicate) ameliorate colitis in rats. J Biol Chem 2009;284:11267-78.
75. Belmiro C, Goncalves R, Kozlowski E, et al. Dermatan sulfate reduces monocyte chemoattractant protein 1 and TGF-/3 production, as well as macrophage recruitment and myofbroblast accumulation in mice with unilateral ureteral obstruction. Braz J Med Biol Res 2011;44:624-33.
76. Godoy J, Block D, Tollefsen D, Werneck C, Vicente C. Dermatan sulfate and bone marrow mononuclear cells used as a new therapeutic strategy after arterial injury in mice. Cyto-therapy 2011;13:695-704.
77. Dhahri M, Abed A, Lajimi R, et al. Grafting of dermatan sulfate on polyethylene terephtalate to enhance biointegration. J Biomed Mater Res A 2011;98:114-21.
78. Nenci GG. Dermatan sulphate as an antithrombotic drug. Pathophysiol Haemost Thromb 2002;32:303-7. (Pubitemid 37490558)
79. Tovar A, de Mattos D, Stelling M, Sarcinelli-Luz B, Nazareth R, Mourao P. Dermatan sulfate is the predominant antithrombotic glycosaminoglycan in vessel walls: implications for a possible physiological function of heparin cofactor II. Biochim Biophys Acta 2005;1740:45-53. (Pubitemid 40692697)
80. Volpi N. Therapeutic applications of glycosaminoglycans. Curr Med Chem 2006;13:1799-810. (Pubitemid 43871757)
81. Saivin S, Cambus JP, Thalamas C, et al. Pharmacokinetics and pharmacodynamics of intramuscular dermatan sulfate revisited: a single- and repeated-dose study in healthy volunteers. Clin Drug Invest 2003;23:533-43. (Pubitemid 37041010)
82. DiPietro L. Wound healing: the role of the macrophage and other immune cells. Shock 1995;4:233-40.
83. Guo S, DiPietro L. Factors affecting wound healing. J Dent Res 2010;89:219-29.
84. Hunt T, Hopf H, Hussain Z. Physiology of wound healing. Adv Skin Wound Care 2000;13(2 Suppl):6-11.
85. Szpaderska AM, DiPietro L. Infammation in surgical wound healing: friend or foe? Surgery 2005;137:571-3.
86. Franz MG, Steed DL, Robson MC. Optimizing healing of the acute wound by minimizing complications. Curr Probl Surg 2007;44:691-763. (Pubitemid 350129811)
87. Spanholtz TA, Theodorou P, Amini P, Spilker G. Severe burn injuries. Deutsches Ärzteblatt Int 2009;106:607-13.
88. Kagan RJ, Peek MD, Ahrenholz DH, et al. Surgical management of the burn wound and use of skin substitutes. American Burn Association White Paper; 2009.
89. Polavarapu N, Ogilvie MP, Panthaki ZJ. Microbiology of burn wound infections. J Craniofac Surg 2008;19:899-902.
90. Ramakrishnan MK, Sankar J, Venkatraman J, Ramesh J. Infections in burn patients\-experience in a tertiary care hospital. Burns 2006;32:594-6.
91. Villanueva E, Bennett MH, Wasiak J, Lehm JP. Hyperbaric oxygen therapy for thermal burns. In: Cochrane database of systematic reviews (Online): The Cochrane Library. Chichester, UK: John Wiley & Sons, Ltd.; 2004.
92. Atiyeh BS, Costagliola M. Cultured epithelial autograft (CEA) in burn treatment: three decades later. Burns 2007;33:405-13. (Pubitemid 46702394)
93. Lazarus G, Cooper D, Knighton D, et al. Defnitions and guidelines for assessment of wounds and evaluation of healing. Arch Dermatol 1994;130:489-93. (Pubitemid 24123372)
94. Russo CA, Steiner C, Spector W. Hospitalizations related to pressure ulcers, 2006. HCUP Statistical Brief #64. Rockville, MD: Agency for Healthcare Research and Quality; 2008.
95. Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2007. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2008.
96. Reiber GE. The epidemiology of diabetic foot problems. Diabet Med 1996;13(Supp 1):S6-11.
97. Stockl K, Vanderplas A, Tafesse E, Chang E. Costs of lower-extremity ulcers among patients with diabetes. Diabetes Care 2004;27:2129-34. (Pubitemid 39167174)
98. Ramsey SD, Newton K, Blough D, et al. Incidence, outcomes, and cost of foot ulcers in patients with diabetes. Diabetes Care 1999;22:382-387. (Pubitemid 29106890)
99. Gottrup F. A specialized wound-healing center concept: importance of a multidisciplinary department structure and surgical treatment facilities in the treatment of chronic wounds. Am J Surg 2004;187:38S-43S.
100. Jameson J, Ugarte K, Chen N, et al. A role for skin gammadelta T cells in wound repair. Science 2002; 296:747-9. (Pubitemid 34442005)